<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938326</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-SIDG-GS-PII</org_study_id>
    <nct_id>NCT01938326</nct_id>
  </id_info>
  <brief_title>Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) Versus Totally Laparoscopic Distal Gastrectomy (TLDG)</brief_title>
  <official_title>Prospective Randomized Controlled Study of Acute Inflammatory Reaction and Morbidity After Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) and Totally Laparoscopic Distal Gastrectomy (TLDG) for Early Gastric Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Compare the immune response and postoperative complications between pure SIDG
           (single-incision laparoscopic distal gastrectomy) and TLDG (totally laparoscopic distal
           gastrectomy) for early gastric cancer (EGC)

        2. Validate the safety, usefulness, minimal invasiveness and feasibility of SIDG (EGC)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are some trends of reducing the numbers and lengths of wounds in the fields of
      laparoscopic surgery.

      Recently, Beyond laparoscopy-assisted distal gastrectomy (LADG), which has the
      mini-laparotomy, TLDG, which has no mini-laparotomy in epigastrium but in umbilicus, has been
      popular procedure in the treatment of gastric cancer. Furthermore, the report on early
      experience of SIDG, which has no incision except umbilicus port, is going to be published.

      However, there've been no objective reports and data on real minimal invasiveness and
      benefits between 2 procedures. In this study, I would like to find out the benefits of the
      reducing port and wound size by comparing the above 2 procedures' immune response and
      postoperative complications.

      This study is planned as a phase II study.

      There are no references on this subject, so the investigators set the numbers of each groups
      into 30, which is minimal requirement for the parametric comparisons.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life - European organization for research and treatment of cancer (EORTC) &amp; Gastrointestinal quality of life index (GIQLI) preoperative</measure>
    <time_frame>within 14 days before surgery</time_frame>
    <description>EORTC and GIQLI questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life - European organization for research and treatment of cancer (EORTC) &amp; Gastrointestinal quality of life index (GIQLI) - postoperative 5 days</measure>
    <time_frame>5 days after surgery (plus and minus 12 hours)</time_frame>
    <description>EORTC and GIQLI questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life - European organization for research and treatment of cancer (EORTC) &amp; Gastrointestinal quality of life index (GIQLI) - postoperative 1 month</measure>
    <time_frame>1 month after surgery (plus and minus 1 week)</time_frame>
    <description>EORTC and GIQLI questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life - European organization for research and treatment of cancer (EORTC) &amp; Gastrointestinal quality of life index (GIQLI) - postoperative 3 months</measure>
    <time_frame>3 months after surgery (plus and minus 1 week)</time_frame>
    <description>EORTC and GIQLI questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numerical rating scale (NRS) for cosmetic result</measure>
    <time_frame>1 month after surgery (plus and minus 1 week)</time_frame>
    <description>Cosmetic result assessed by NRS (0~10, 0: worst - 10 : best, no scar)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numerical rating scale (NRS) for cosmetic result</measure>
    <time_frame>3 month after surgery (plus and minus 1 week)</time_frame>
    <description>Cosmetic result assessed by NRS (0~10, 0: worst - 10 : best, no scar)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) for pain assessment - Postoperative 2hrs</measure>
    <time_frame>within 2 hours after surgery</time_frame>
    <description>Pain assessment VAS (O: no pain, 10: worst pain, imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) for pain assessment - Postoperative 1 day</measure>
    <time_frame>1 day after surgery (plus and minus 6 hours)</time_frame>
    <description>Pain assessment VAS (O: no pain, 10: worst pain, imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) for pain assessment - Postoperative 2 days</measure>
    <time_frame>2 days after surgery (plus and minus 6 hours)</time_frame>
    <description>Pain assessment VAS (O: no pain, 10: worst pain, imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) for pain assessment - Postoperative 3 days</measure>
    <time_frame>3 days after surgery (plus and minus 6 hours)</time_frame>
    <description>Pain assessment VAS (O: no pain, 10: worst pain, imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) for pain assessment - Postoperative 5 days</measure>
    <time_frame>5 days after surgery (plus and minus 6 hours)</time_frame>
    <description>Pain assessment VAS (O: no pain, 10: worst pain, imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>within the first 30 days after surgery</time_frame>
    <description>Postoperative complications assessed by Clavien-Dindo Classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute inflammatory Response - Preoperative</measure>
    <time_frame>within 1 weeks before surgery</time_frame>
    <description>Check white blood cell (WBC) count, c-reactive protein (CRP), tumor necrosis factor (TNF)-a, interleukin (IL-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute inflammatory Response - Postoperative 2 hours</measure>
    <time_frame>2 hours after surgery (plus and minus 1 hours)</time_frame>
    <description>Check white blood cell (WBC) count, c-reactive protein (CRP), tumor necrosis factor (TNF)-a, interleukin (IL-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute inflammatory Response - Postoperative 2 days</measure>
    <time_frame>2 days after surgery (plus and minus 6 hours)</time_frame>
    <description>Check white blood cell (WBC) count, c-reactive protein (CRP), tumor necrosis factor (TNF)-a, interleukin (IL-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute inflammatory Response - Postoperative 5 days</measure>
    <time_frame>5 day after surgery (plus and minus 6 hours)</time_frame>
    <description>Check white blood cell (WBC) count, c-reactive protein (CRP), tumor necrosis factor (TNF)-a, interleukin (IL-6)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Early Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>TLDG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No mini-laparotomy in the epigastrium Reconstruction by the uncut Roux-en Y gastrojejunostomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SIDG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SIDG : pure single incision laparoscopic distal gastrectomy Reconstruction by the uncut Roux-en Y gastrojejunostomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Approach Method</intervention_name>
    <description>SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)</description>
    <arm_group_label>TLDG</arm_group_label>
    <arm_group_label>SIDG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinically early gastric cancer, potentially possible to perform distal gastrectomy

          -  20&lt; Age &lt; 80

          -  No severe comorbidity

          -  No other malignancy

          -  No Other cancer treatments

          -  BMI &lt; 23 in man, BMI &lt; 25 in woman

        Exclusion Criteria:

          -  Other reconstruction method except Billroth I
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hyung-Ho Kim, M.D., Ph.D.</last_name>
    <phone>+82-31-787-7097</phone>
    <email>hhkim@snubh.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sang-Hoon Ahn, M.D.</last_name>
    <phone>+82-31-787-7106</phone>
    <email>viscaria@snubh.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung-Ho Kim, M.D, Ph.D.</last_name>
      <phone>+82-31-787-7097</phone>
      <email>hhkim@snubh.org</email>
    </contact>
    <contact_backup>
      <last_name>Sang-Hoon Ahn, M.D.</last_name>
      <phone>+82-31-787-7099</phone>
      <email>viscaria@snubh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Hyung-Ho Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2012</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Sang-Hoon Ahn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stomach neoplasm</keyword>
  <keyword>TLDG</keyword>
  <keyword>SIDG</keyword>
  <keyword>single-port</keyword>
  <keyword>inflammatory response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

